You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParomomycin
Accession NumberDB01421
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Structure
Thumb
Synonyms
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
Aminosidin
Aminosidine
Catenulin
Crestomycin
Estomycin
Hydroxymycin
Monomycin a
Neomycin e
Paromomicina
PAROMOMYCIN
Paromomycin i
Paromomycine
Paromomycinum
Paucimycin
Paucimycinum
R 400
R-400
Zygomycin a1
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Humatin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Paromomycin SulfateCapsule250 mg/1OralHeritage Pharmaceuticals Inc.2009-10-22Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralSun Pharmaceutical Industries, Inc.1997-06-30Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralDepartment Of State Health Services, Pharmacy Branch2009-10-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HumatinParke Davis (now Pfizer)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paromomycin sulfate
1263-89-4
Thumb
  • InChI Key: LJRDOKAZOAKLDU-UDXJMMFXSA-N
  • Monoisotopic Mass: 713.263680415
  • Average Mass: 713.707
DBSALT000265
Categories
UNII61JJC8N5ZK
CAS number7542-37-2
WeightAverage: 615.6285
Monoisotopic: 615.296301173
Chemical FormulaC23H45N5O14
InChI KeyUOZODPSAJZTQNH-LSWIJEOBSA-N
InChI
InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[[email protected]](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[[email protected]](N)C[[email protected]](N)[[email protected]]3O[[email protected]]3O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]3N)[C@@H]2O)[[email protected]](N)[C@@H](O)[C@@H]1O
Pharmacology
IndicationFor the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
Structured Indications
PharmacodynamicsParomomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.
Mechanism of actionParomomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.
TargetKindPharmacological actionActionsOrganismUniProt ID
30S ribosomal protein S10Proteinyes
inhibitor
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)Q5SHN7 details
16S rRNANucleotideyes
inhibitor
Enteric bacteria and other eubacterianot applicabledetails
Related Articles
AbsorptionPoorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Paromomycin Action PathwayDrug actionSMP00714
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Paromomycin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Alendronic acidParomomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Paromomycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
AmpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Paromomycin.Investigational
ApremilastApremilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Atracurium besylateParomomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Paromomycin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
Botulinum Toxin Type AParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paromomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Paromomycin.Approved
CarbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinParomomycin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Paromomycin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateParomomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Paromomycin.Approved
ClodronateParomomycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateParomomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineParomomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
DecamethoniumParomomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Paromomycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Paromomycin.Approved
Domoic AcidParomomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideParomomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Etidronic acidParomomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Paromomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Paromomycin.Approved, Vet Approved
Gallamine TriethiodideParomomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
IbandronateParomomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MecamylamineParomomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Paromomycin can be decreased when it is combined with Meticillin.Approved
MetocurineParomomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideParomomycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumParomomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Paromomycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
NeosaxitoxinParomomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Paromomycin.Approved
OxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
PamidronateParomomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumParomomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumParomomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Paromomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Paromomycin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
PyrantelParomomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumParomomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental, Investigational
RisedronateParomomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumParomomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
SuccinylcholineParomomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Paromomycin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Paromomycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Paromomycin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateParomomycin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateParomomycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Paromomycin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Paromomycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateParomomycin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.Approved
TranilastTranilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TubocurarineParomomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Paromomycin.Approved
VecuroniumParomomycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidParomomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
Food Interactions
  • Take with food.
References
Synthesis Reference

Federico Arcamone, Giuseppe Cassinelli, “Paromomycin derivatives and process for the preparation thereof.” U.S. Patent US4021601, issued October, 1967.

US4021601
General References
  1. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58. [PubMed:11587639 ]
External Links
ATC CodesA07AA06
AHFS Codes
  • 08:30.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Paromomycin 250 mg capsule5.67USD capsule
Humatin 250 mg capsule2.67USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility79.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-8.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.23ChemAxon
pKa (Strongest Basic)9.94ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area347.32 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity134.24 m3·mol-1ChemAxon
Polarizability60.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,5-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Disaccharide
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
Part of the top of the 30S subunit head.
Gene Name:
rpsJ
Uniprot ID:
Q5SHN7
Molecular Weight:
11929.82 Da
References
  1. Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [PubMed:19438282 ]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Konno T, Kurita D, Takahashi T, Muto A, Himeno H: Initiation-shift of trans-translation by aminoglycosides. Nucleic Acids Symp Ser (Oxf). 2004;(48):299-300. [PubMed:17150597 ]
  4. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988 ]
Comments
comments powered by Disqus
Drug created on July 24, 2007 04:03 / Updated on August 17, 2016 12:23